Rituximab in Metastatic Melanoma

Summary

The purpose of this study is to determine whether rituximab as an adjuvant therapy in clinical stage IIIc / IV (no evidence of disease, AJCC (American Joint Committee on Cancer) 2002) melanoma patients is safe and prolongs overall survival and disease-free interval.

Timeline

Start

2007-10

Primary completion

2011-05

Completion

2011-05

Outcome

Outcome not reported

Stopped (Enrollment): “the only reason is that recruitment was not sufficient to meet the planned patient numbers, because complete remissions are still infrequent.”

Drugs

Indications